60 Degrees Pharma Shares Are Trading Lower After The Company Withdrew Covid Phase 2B Investigational New Drug, It Will Resubmit Pending Assessment Of Ability To Meet FDA Requirements
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharma has withdrawn its Covid Phase 2B Investigational New Drug, with plans to resubmit after assessing its ability to meet FDA requirements. This has led to a decrease in the company's share price.
September 19, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
60 Degrees Pharma's decision to withdraw its Covid Phase 2B Investigational New Drug and resubmit after assessing FDA requirements has negatively impacted its share price.
The company's decision to withdraw its drug for reassessment indicates potential regulatory issues, which can negatively impact investor confidence and lead to a decrease in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100